InSysBio to present a poster at PAGE Meeting 2023

events
Conference
May 30, 2023

InSysBio announces its participation in the 31st PAGE Meeting 2023 which is to be held at the Palexco Convention and Exhibition Centre, A Coruna, Spain on June 28-30, 2023. InSysBio team presents a poster within its frames:

Poster Session II - Methodology - Estimation Methods

Wednesday 15:35-17:00, June 28

Our latest posters: InSysBio team posters

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

March 2024
MoTuWeThFrSaSu
    
1
2
3
4
5
6
1. 06 Mar 2024 12:40 InSysBio to present posters at ASCPT 2024 Annual Meeting InSysBio announces its participation in the ASCPT 2024 Annual Meeting which is to be held March 27-29, at the Broadmoor in Colorado Springs, CO. Tatiana Karelina, Head of Neurodegenerative Diseases modeling team, and Vladislav Leonov, CYTOCON DB team, will present 4 posters by InSysBio
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Upcoming Events
Tags
Latest News
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator
06.04
InSysBio to release Immune Response Template 3.6.2 for QSP modeling
16.01
InSysBio team to publish the new article “Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study”